Can a blood marker reveal how well lymphoma treatment works?
NCT ID NCT06813573
First seen Oct 05, 2026 · Last updated Oct 06, 2026 · Updated 1 time
Summary
Researchers are studying whether levels of circulating nucleosomes, tiny DNA-protein packages released by dying cells, change during first-line treatment for two types of non-Hodgkin lymphoma: diffuse large B-cell lymphoma and follicular lymphoma. About 40 participants give blood samples before treatment, before each chemotherapy cycle, at the end of treatment, and if the cancer returns. The goal is to see whether nucleosome levels match how well the lymphoma responds to standard R-CHOP chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If nucleosome levels track with treatment response, doctors could one day use a simple blood draw to check how well lymphoma treatment is working.
- What could go wrong
- This small observational study of 40 people may find no clear link between nucleosome levels and response, and it cannot prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
Sep 2024
- Expected to finish
-
Oct 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically proven diagnosis of diffuse large B cell lymphoma or follicular lymphoma, according to the WHO 2016 classification, requiring a first line of treatment with a RCHOP 21 regimen * Agreement to participate after receiving oral and written information on the study Exclusion Criteria: * History of previous treatment for lymphoma (excluding localized low dose radiotherapy in the case of follicular lymphoma) * Treatment with a chemotherapy regimen different from RCHOP21
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy
Villejuif, 94800, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A First-in-Human, phase 1, Open-Label, dose escalation and expansion study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-T0920 in DLBCL and other aggressive B-Cell malignancies
- Engineered immune cells target lymphoma that came back
- Colombia-Made CAR-T cells put to the test against stubborn blood cancers
- A new injectable drug aims at Hard-to-Treat B-Cell cancers
- Immune duo attacks follicular lymphoma in first-line trial
- Three-Drug combo aims to replace chemo in elderly lymphoma